louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00629421: Early Screening of Hepatocellular Carcinoma in Cirrhotic Patients: a Prospective Study
Official title: Early Screening of Hepatocellular Carcinoma in Cirrhotic Patients: a Prospective Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cirrhosis
Hepatocellular Carcinoma
Lead sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital
Sponsor class: OTHER
First posted: 2008-03-06
Enrollment: 1200
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Well-dignosed patients with cirrhosis

Brief summary: Although serum alpha-fetoprotein level and abdominal sonography are the main methods to screening hepatocellular carcinoma (HCC) in cirrhotic patients, the adequate time and methods used are not completely well-defined. This study aims to assess the better timing and methods for prospectively screening HCC in patients with cirrhosis

Detailed description: Well-diagnosed consecutive patients with cirrhosis were enrolled through a designed questionnaire to obtain basic information about gender, age, etiology of cirrhosis, conventional liver function tests, serum AFP level, education level, substance use including smoking, alcohol drinking, betel quid chewing, history of familial HCC, etc. Then the patients was followed by periodic abdominal sonography examination and determination of AFP and liver function. If AFP elevated or liver nodule appears, effort to diagnose HCC will be performed.If HCC was performed, the survival will be followed-up. As anti-viral therapy was found to decrease risk for HCC, patients with those therapy will be excluded.

Eligibility criteria: Inclusion Criteria:

* Image diagnosis or biochemical diagnosis or presence of portal hypertension

Exclusion Criteria:

* Presence of hepatocellular carcinoma

Primary outcomes:
measure: development of hepatocellular carcinoma
timeFrame: during observation
Secondary outcomes:
Other outcomes:
Locations:
city: Kaohsiung
country: Taiwan
facility: Kaohsiung Medical University Chung-Ho Memorial Hospital
Study officials:
affiliation: Kaohsiung Medical University
name: Jung-Fa Tsai, M.D., Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02870621: Volume of Perirenal Fat and Chronic Kidney Disease
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Nephrectomy
Lead sponsor: Centre Hospitalier Universitaire de Nice
Sponsor class: OTHER
First posted: 2016-08-17
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Recruitment is in hospital, all patients being hospitalized in case of nephrectomy for kidney cancer. The treatment will be done like habitually and fat will be sample.

Brief summary: The perirenal fat may alter renal function by secreting fibrotic inflammatory agents when accumulates during obesity. Nephrectomy for renal tumor is a model that would provide tissue samples to test this hypothesis. Renal tumor could itself be responsible for inflammation and fibrosis in its environment. This study aims to measure the influence of the tumor on his kidney Environment and fat and define molecular markers not influenced by renal tumor. The main objective is to compare the inflammation of the perirenal fat taken in two locations in the same patient, in contact and 4 cm from the outer edge of the tumor, each patient as his own control. The secondary objective is to compare the degree of interstitial fibrosis of the renal cortex in the same sampling methods.


Eligibility criteria: Inclusion Criteria:

* Age 18 years or more
* Indication nephrectomy for kidney tumor
* Stadium T1a, T1b or T2 and M0 according to the TNM (Tumor Nodes Metastasis) classification of tumors

Exclusion Criteria:

* Nephrectomy indication for chronic pyelonephritis
* Asian topic because of the difference threshold values used to characterize the metabolic syndrome in this population
* Diabetes type I or II due to a high score of renal interstitial fibrosis
* Infection with HIV (Human immunodeficiency virus)
* Partial nephrectomy (a part of the kidney on the side of the tumor is left in place)

Primary outcomes:
measure: Numbers of renal interstitial fibrosis
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Nice
country: France
facility: CHU de Nice
Study officials:
References:
Clinical trial NCT06996821: Evaluation of Impacted or Included Maxillary Canines on Dentofacial Structures, and Airway and Nasal Fossa Dimensions
Official title: Evaluation of Impacted or Included Maxillary Canines on Dentofacial Structures, and Airway and Nasal Fossa Dimensions
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Impacted Canines
Maxillary Sinus
Lead sponsor: University of Salamanca
Sponsor class: OTHER
First posted: 2025-05-30
Enrollment: 90
Sex: ALL
Minimum age (years): 10
Maximum age (years): 23
Standard ages: CHILD
ADULT
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Orthodontic Department of Alfonxo X Sabio Masters' Clinics

Brief summary: The study retrospectively analyzed previously acquired CBCT images to evaluate specific anatomical features, such as \[e.g., "maxillary sinus and nasal fossa volumes"\]. No active patient participation or new clinical procedures is required; this information is used to measure sinus and fossa dimensions.

Detailed description: The study analysed the CBCTs of patients, each assigned to one of three groups: control, unilateral canine impaction, or bilateral canine impaction. Each group was assigned by gender. Three values were analysed: maxillary sinuses left (MSL) and right (MSR), and sinuses with fossa MSNF measures in mm3.

Eligibility criteria: Inclusion Criteria:

* unilateral or bilateral canine inclusion,
* young pacients between 10 and 23 years old.

Exclusion Criteria:

* pregnant women,
* major craniofacial deformities (such as cleft palate, severe asymmetric malocclusion, trauma or head \& neck oncologic surgery),
* surgeries other than maxillomandibular advancement,
* patients with maxillary compression or syndromes
* any nasal or nasopharyngeal airway obstruction.
* skeletal, dental or dentoalveolar transversal or vertical issues

Primary outcomes:
measure: Different Volumes of Maxillary Sinuses and Nasal Airway Complex
timeFrame: November 2024 to February 2025
Secondary outcomes:
Other outcomes:
Locations:
city: Madrid
country: Spain
facility: Universidad de Salamanca
Study officials:
References:
Clinical trial NCT05200221: A Single Center Real-world Study of Donafenib in the Treatment of Hepatocellular Carcinoma in Routine Clinical Practice
Official title: A Single Center Real-world Study of Donafenib in the Treatment of Hepatocellular Carcinoma (HCC) in Routine Clinical Practice
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Donafenib
Hepatocellular Carcinoma
Lead sponsor: Shanghai Zhongshan Hospital
Sponsor class: OTHER
First posted: 2022-01-20
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: It is planned to include 300 patients with unresectable hepatocellular carcinoma treated with Donafenib.

Brief summary: This trial is a single center observational real-world study. It is planned to include 300 patients with unresectable hepatocellular carcinoma (uHCC) treated with Donafenib. The purpose of the study was to observe the effectiveness and safety of Donafenib in the real world.


Eligibility criteria: Inclusion Criteria:

1. Age ≥ 18 years old;
2. Histologically confirmed HCC or meet the clinical diagnostic criteria of HCC;
3. Unresectable HCC;
4. The doctor decided to use donafenib before the patient was enrolled in the study；
5. Informed consent and willing to complete the study according to the protocol.

Exclusion Criteria:

1. Those who are participating in clinical trials of other antitumor drugs;
2. Allergic to any component of Donafenib tablets;
3. Patients with active bleeding, active peptic ulcer, drug uncontrollable hypertension or severe liver dysfunction;
4. Pregnant or lactating women.

Primary outcomes:
measure: Incidence of adverse events and serious adverse events.
timeFrame: an average of 1.5 year.
Secondary outcomes:
measure: Objective response rate (ORR)
timeFrame: an average of 1 year.
measure: Duration of remission (DoR)
timeFrame: an average of 1 year.
measure: Disease control rate (DCR)
timeFrame: an average of 1 year
measure: Progression-free survival(PFS)
timeFrame: an average of 1 year
measure: overall survival(OS)
timeFrame: an average of 1 year
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Zhongshan Hospital, Fudan University,
state: Shanghai
Study officials:
affiliation: Zhongshan Hospital, Fudan University, Shanghai, China.
name: Jian Zhou, M.D., Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02808221: Readmission in the Case of Patients With Heart Failure
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Heart Failure
Keywords: Heart failure
heart disease
left ventricular
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2016-06-21
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with heart failure.

Brief summary: Heart failure (HF) is a serious chronic disease with frequent readmissions, some of which can be prevented by early action. The management of HF is complex: long, often difficult and costly. In France, nearly one million people suffer from HF and 120,000 new cases are diagnosed every year. With the aging population, this number will continue to evolve and become a real public health problem. Within 10 to 20 years ahead, WHO projects that heart failure in either the 3 most common diseases in industrialized countries.

Investigators goals are to make an inventory of PRADO-IC project in terms of its effectiveness on readmission of patients with heart failure.


Eligibility criteria: Inclusion Criteria:

* Patient aged 18 or over
* Patient readmitted for heart failure

Exclusion Criteria:

* Population whose age is less than 18 years

Primary outcomes:
measure: The cost of re-hospitalization in the case of patients with heart failure reach
timeFrame: during 2015
Secondary outcomes:
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Service de Médecine Interne, diabète et maladies métaboliques - Médicale B
Study officials:
affiliation: University Hospital, Strasbourg, France
name: Emmanuel ANDRES, MD, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT02396121: Micronutrient and Malnourished Elderly
Official title: Évaluation de l'évolution du Statut Nutritionnel en Micronutriment Chez Les Patients âgés dénutris bénéficiant d'Une complémentation Nutritionnelle Orale
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Malnourished Elderly
Lead sponsor: Société des Produits Nestlé (SPN)
Sponsor class: INDUSTRY
First posted: 2015-03-24
Enrollment: 67
Sex: ALL
Minimum age (years): 70
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the micronutrient status of malnourished elderly after oral nutritional supplementation.


Eligibility criteria: Inclusion Criteria:

* Age : above or equal to 70 years

AND :

* Weight loss above or equal to 5% in one month
* OR weight loss above or equal to 10% in 6 months
* OR BMI between 18 and 21
* OR albuminaemia between 30 and 35 g/L
* OR MNA-SF less or equal to 7

Exclusion Criteria:

* Severe malnutrition
* Contraindication to oral nutrition
* Severe pathologies
* Inflammatory syndrome (CRP \> 30 mg/L)
* Severe dementia (Mini Mental Score \< 10)

Primary outcomes:
measure: Change from baseline in micronutrients status after 28 days
timeFrame: 28 days
Secondary outcomes:
measure: Nutritional status
timeFrame: 28 days
measure: Body composition
timeFrame: 28 days
measure: Compliance
timeFrame: 28 days
measure: Autonomy
timeFrame: 28 fays
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02272621: Bleeding in Partial Upper Hemisternotomy Versus Full Sternotomy Aortic Valve Replacement
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Aortic Valve Stenosis
Heart Valve Diseases
Lead sponsor: Karolinska University Hospital
Sponsor class: OTHER
Collaborators: name: Karolinska Institutet
First posted: 2014-10-23
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a single-center, open-label, randomized controlled trial. Patients scheduled for aortic valve replacement (AVR) at Karolinska University Hospital in Stockholm, Sweden will be eligible. One-hundred patients will be randomly assigned to either partial upper sternotomy (50 patients) or full sternotomy AVR (50 patients). Inclusion criteria is severe aortic stenosis referred for medically indicated isolated aortic valve replacement. Exclusion criteria are inclusion in other trial, left ventricular ejection fraction less than 0.45, previous cardiac surgery, or urgent/emergent surgery.

Mechanical and bioprosthetic (stented or sutureless) aortic valves will be implanted. Clinical characteristics will be registered. Clinical postoperative outcomes including bleeding outcomes will be registered. Routine blood sampling will be performed pre- and postoperatively. All available data will be collected prospectively. Informed consent will be obtained from patients meeting the inclusion criteria before the initiation of any study-specific procedures.


Eligibility criteria: Inclusion Criteria:

* ≥ 18 years of age
* Severe aortic stenosis defined as aortic valve area of less than 1 cm2 or index area of 0.6 cm2/m2 by echocardiography
* Referred for medically indicated aortic valve replacement
* Sinus rhythm
* Provide written informed consent

Exclusion Criteria:

* Inclusion in other trial
* Left ventricular ejection fraction less than 0.45
* Presence of any coexisting severe valvular disorder
* Previous cardiac surgery
* Urgent or emergent surgery

Primary outcomes:
measure: Universal definition of perioperative bleeding in adult cardiac surgery
timeFrame: Within 3 days from surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Stockholm
country: Sweden
facility: Department of Cardiothoracic Surgery, Karolinska University Hospital
Study officials:
References:
Clinical trial NCT00660764: Assessment of the Efficacy of Rosuvastatin in Patient Groups With a Dissimilar Risk Profile in an Observational Study (HEROS)
Official title: Assessment of the Efficacy of Rosuvastatin in Patient Groups With a Dissimilar Risk Profile in an Observational Study (HEROS)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hypercholesterolemia
Coronary Heart Disease
Peripheral Vascular Disease
Cerebrovascular Accident
Diabetes
Keywords: cholesterol
coronary heart disease
rosuvastatin
LDL-C goal
hypercholesterolemia
secondary prevention
primary prevention
CVA
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2008-04-17
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients of practices of General Practioners

Brief summary: In an observational multi-centre study (HEROS), the effects of starting treatment with rosuvastatin were assessed, on low-density lipoprotein cholesterol (LDL-C) goal achievement, in patients with a dissimilar high-risk profile who had not been treated with cholesterol lowering drugs at least in the past three months. Also set-up costs of rosuvastatin treatment and proportional changes in LDL-C and high-density lipoprotein cholesterol (HDL-C) were studied.


Eligibility criteria: Inclusion Criteria:

* patients who had not been treated with cholesterol lowering drugs at least in the past three months, with an LDL-C 3.2 mmol/l.
* According to the advise of the CBO, and could be included in one of the following risk groups: secondary prevention, DM or primary prevention.
* The general practice investigator made the decision to start treatment with rosuvastatin irrespective of study participation.
* Patient approved to place anonymous results at the disposal of AstraZeneca

Exclusion Criteria:

* Patients with symptoms of myalgia, myopathy or liver function insufficiency (including raised serum transaminases) which bear a causal relation to the treatment with statins, patients with familiar dyslipidemia and/or patients with contra-indications for treatment with rosuvastatin

Primary outcomes:
measure: Effects of starting treatment with rosuvastatin were assessed, on low-density lipoprotein cholesterol (LDL-C) goal achievement, in patients with a dissimilar high-risk profile who hadn't been treated with cholesterol lowering drugs in the past 3 months.
timeFrame: 2 year
Secondary outcomes:
measure: Also set-up costs of rosuvastatin treatment and proportional changes in LDL-C and high-density lipoprotein cholesterol (HDL-C) were studied.
Other outcomes:
Locations:
Study officials:
affiliation: CV
name: Ingrid van Geel
role: STUDY_CHAIR
affiliation: CV
name: Ingeborg Vosjan
role: STUDY_CHAIR
References:
Clinical trial NCT01744964: Apomorphine Effects on Experimental Pain
Official title: Alterations in the Ability to Tolerate Experimental Pain by Apomorphine and Its Association With a Dopamine Transporter Polymorphism
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Healthy
Keywords: apomorphine
dopamine transporter gene
SLC6A3
cold pressor test
tolerance
experimental pain
dopamine agonist
Lead sponsor: Rambam Health Care Campus
Sponsor class: OTHER
First posted: 2012-12-07
Enrollment: 105
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The aims of this study were to assess the effects of the dopamine agonist apomorphine on experimental pain models in healthy subjects and to explore the possible association between these effects and a common polymorphism within the dopamine transporter gene.

Detailed description: Healthy volunteers (n=105) participated in this randomized double-blind, placebo-controlled, cross-over trial. Heat pain threshold and intensity, cold pain threshold, and the response to tonic cold pain (latency, intensity, and tolerance) were evaluated before and for up to 120 min after the administration of 1.5 mg apomorphine/placebo. A polymorphism (DAT-1) within the dopamine transporter gene (SLC6A3) was investigated.

Eligibility criteria: Inclusion Criteria:

- healthy and free from chronic pain of any type did not use any medications other than oral contraceptives were able to understand the purpose and instructions of the study.

Exclusion Criteria:

- any type of medical or painful condition use of medications or recreational drugs pregnancy.

Primary outcomes:
measure: Cold pain tolerance
timeFrame: 120 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Haifa
country: Israel
facility: Rambam Health Care Campus
Study officials:
affiliation: Rambam Health Care Campus, Haifa, Israel
name: Elon Eisenberg, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00584064: Emergency/Compassionate Use PFO Occluder
Study type: EXPANDED_ACCESS
Overall status: APPROVED_FOR_MARKETING
Conditions: Patent Foramen Ovale
PFO
Keywords: patent
foramen
ovale
PFO
Lead sponsor: Abbott Medical Devices
Sponsor class: INDUSTRY
First posted: 2008-01-02
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT

Brief summary: Emergency/compassionate use for the AMPLATZER PFO Occluder


Eligibility criteria: Inclusion Criteria:

* Emergency/compassionate use for patients not meeting the inclusion criteria for the AMPLATZER PFO Access Registry.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06253364: VETC is an Effective Marker for Postoperative Adjuvant Immunotherapy
Official title: A Robust Biomarker of Aggressive HCC and the Response for Adjuvant PD-1 Inhibitors or Combined TKIs Following Liver Resection: Vessels That Encapsulate Tumor Clusters
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: HCC
Recurrence
Lead sponsor: Tongji Hospital
Sponsor class: OTHER
First posted: 2024-02-12
Enrollment: 462
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who met the inclusion and exclusion criteria were retrospectively collected for this study.

Brief summary: Vessels that encapsulate tumor clusters (VETC) is an invasive metastatic factor in HCC independent of the epithelial mesenchyme transition (EMT), and VETC-positive patients have a higher rate of postoperative recurrence. However, it is not clear how the surgical prognosis of VETC-positive patients can be improved.

Detailed description: Previous studies have identified VETC as a new metastatic pattern independent of EMT that may be associated with immunosuppression as well as poor prognosis. Multiple retrospective studies find higher rates of postoperative recurrence, distant metastasis in VETC-positive patients. How to improve surgical prognosis in VETC-positive patients needs to be explored. There is no consensus on postoperative adjuvant therapy for HCC. In recent years, adjuvant immunotherapy (sintilimab) and adjuvant immunotherapy combined with targeted therapy (T+A) have been shown to be effective in improving the surgical prognosis. Therefore, the investigators retrospectively collected three surgical resection cohorts, the surgical resection alone group, the postoperative adjuvant PD-1 monotherapy group, and the postoperative adjuvant PD-1 monotherapy combined with Lenvatinib group, to compare these postoperative adjuvant therapies in a subgroup of VETC patients.

Eligibility criteria: Inclusion Criteria:

* Underwent radical hepatectomy
* No preoperative treatment
* Pathological confirmed HCC
* High-risk recurrent HCC
* Not receiving any adjuvant therapy or receiving adjuvant therapy with PD-1 monotherapy or receiving adjuvant therapy with PD-1 monotherapy in combination with Lenvatinib after surgery

Exclusion Criteria:

* Macrovascular invasion
* No available wax blocks
* No complete clinical information

Primary outcomes:
measure: Disease -free survival
timeFrame: From date of include in this research until the date of first documented recurrence or date of death from any cause, whichever came first, assessed up to 60 months
Secondary outcomes:
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
state: Hubei
Study officials:
References: